Cargando…

Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals

It has been demonstrated that after two doses, SARS-CoV-2 mRNA vaccine-induced neutralizing antibodies against Omicron subvariants are much lower than against wild type virus and a booster dose greatly increases Omicron neutralization. We compared Spike-binding IgG responses against wild type virus...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuzel, Timothy G, Fu, Jia, Anderson, Mark, Stec, Michael, Boler, Michael, Behun, Dylan, Gosha, Amy, Cloherty, Gavin, Landay, Alan, Moy, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789750/
https://www.ncbi.nlm.nih.gov/pubmed/36572601
http://dx.doi.org/10.1016/j.vaccine.2022.12.049
_version_ 1784859022057275392
author Kuzel, Timothy G
Fu, Jia
Anderson, Mark
Stec, Michael
Boler, Michael
Behun, Dylan
Gosha, Amy
Cloherty, Gavin
Landay, Alan
Moy, James
author_facet Kuzel, Timothy G
Fu, Jia
Anderson, Mark
Stec, Michael
Boler, Michael
Behun, Dylan
Gosha, Amy
Cloherty, Gavin
Landay, Alan
Moy, James
author_sort Kuzel, Timothy G
collection PubMed
description It has been demonstrated that after two doses, SARS-CoV-2 mRNA vaccine-induced neutralizing antibodies against Omicron subvariants are much lower than against wild type virus and a booster dose greatly increases Omicron neutralization. We compared Spike-binding IgG responses against wild type virus and four SARS-CoV-2 Omicron subvariants in infection-naïve and previously-infected (hybrid immunity) individuals after the second and the third (booster) dose of BNT162b2. In both groups of individuals, antibodies for all four Omicron subvariants were lower than wild type antibodies. Compared to infection-naïve individuals, hybrid immunity resulted in higher antibodies levels after 2 doses of vaccine but not after the booster. In both groups, antibodies for wild type and all Omicron subvariants waned over an 8-month period post second dose but rebounded after the booster. These results underscore the importance of boosters to restore diminishing antibody levels for both infection-naïve and previously-infected individuals.
format Online
Article
Text
id pubmed-9789750
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-97897502022-12-27 Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals Kuzel, Timothy G Fu, Jia Anderson, Mark Stec, Michael Boler, Michael Behun, Dylan Gosha, Amy Cloherty, Gavin Landay, Alan Moy, James Vaccine Short Communication It has been demonstrated that after two doses, SARS-CoV-2 mRNA vaccine-induced neutralizing antibodies against Omicron subvariants are much lower than against wild type virus and a booster dose greatly increases Omicron neutralization. We compared Spike-binding IgG responses against wild type virus and four SARS-CoV-2 Omicron subvariants in infection-naïve and previously-infected (hybrid immunity) individuals after the second and the third (booster) dose of BNT162b2. In both groups of individuals, antibodies for all four Omicron subvariants were lower than wild type antibodies. Compared to infection-naïve individuals, hybrid immunity resulted in higher antibodies levels after 2 doses of vaccine but not after the booster. In both groups, antibodies for wild type and all Omicron subvariants waned over an 8-month period post second dose but rebounded after the booster. These results underscore the importance of boosters to restore diminishing antibody levels for both infection-naïve and previously-infected individuals. Elsevier Ltd. 2023-01-23 2022-12-24 /pmc/articles/PMC9789750/ /pubmed/36572601 http://dx.doi.org/10.1016/j.vaccine.2022.12.049 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Short Communication
Kuzel, Timothy G
Fu, Jia
Anderson, Mark
Stec, Michael
Boler, Michael
Behun, Dylan
Gosha, Amy
Cloherty, Gavin
Landay, Alan
Moy, James
Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals
title Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals
title_full Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals
title_fullStr Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals
title_full_unstemmed Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals
title_short Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals
title_sort effects of a booster dose of bnt162b2 on spike-binding antibodies to sars-cov-2 omicron ba.2, ba.3, ba.4 and ba.5 subvariants in infection-naïve and previously-infected individuals
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789750/
https://www.ncbi.nlm.nih.gov/pubmed/36572601
http://dx.doi.org/10.1016/j.vaccine.2022.12.049
work_keys_str_mv AT kuzeltimothyg effectsofaboosterdoseofbnt162b2onspikebindingantibodiestosarscov2omicronba2ba3ba4andba5subvariantsininfectionnaiveandpreviouslyinfectedindividuals
AT fujia effectsofaboosterdoseofbnt162b2onspikebindingantibodiestosarscov2omicronba2ba3ba4andba5subvariantsininfectionnaiveandpreviouslyinfectedindividuals
AT andersonmark effectsofaboosterdoseofbnt162b2onspikebindingantibodiestosarscov2omicronba2ba3ba4andba5subvariantsininfectionnaiveandpreviouslyinfectedindividuals
AT stecmichael effectsofaboosterdoseofbnt162b2onspikebindingantibodiestosarscov2omicronba2ba3ba4andba5subvariantsininfectionnaiveandpreviouslyinfectedindividuals
AT bolermichael effectsofaboosterdoseofbnt162b2onspikebindingantibodiestosarscov2omicronba2ba3ba4andba5subvariantsininfectionnaiveandpreviouslyinfectedindividuals
AT behundylan effectsofaboosterdoseofbnt162b2onspikebindingantibodiestosarscov2omicronba2ba3ba4andba5subvariantsininfectionnaiveandpreviouslyinfectedindividuals
AT goshaamy effectsofaboosterdoseofbnt162b2onspikebindingantibodiestosarscov2omicronba2ba3ba4andba5subvariantsininfectionnaiveandpreviouslyinfectedindividuals
AT clohertygavin effectsofaboosterdoseofbnt162b2onspikebindingantibodiestosarscov2omicronba2ba3ba4andba5subvariantsininfectionnaiveandpreviouslyinfectedindividuals
AT landayalan effectsofaboosterdoseofbnt162b2onspikebindingantibodiestosarscov2omicronba2ba3ba4andba5subvariantsininfectionnaiveandpreviouslyinfectedindividuals
AT moyjames effectsofaboosterdoseofbnt162b2onspikebindingantibodiestosarscov2omicronba2ba3ba4andba5subvariantsininfectionnaiveandpreviouslyinfectedindividuals